News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
184,875 Results
Type
Article (17753)
Company Profile (120)
Press Release (167002)
Multimedia
Podcasts (33)
Webinars (9)
Section
Business (58310)
Career Advice (946)
Deals (9374)
Drug Delivery (37)
Drug Development (23486)
Employer Resources (72)
FDA (2364)
Job Trends (4261)
News (92386)
Policy (5801)
Tag
Academia (486)
Accelerated approval (1)
Adcomms (13)
Allergies (22)
Alliances (16259)
ALS (41)
Alzheimer's disease (458)
Antibody-drug conjugate (ADC) (95)
Approvals (2322)
Artificial intelligence (116)
Autoimmune disease (17)
Automation (5)
Bankruptcy (83)
Best Places to Work (2893)
BIOSECURE Act (19)
Biosimilars (31)
Biotechnology (111)
Bladder cancer (36)
Brain cancer (14)
Breast cancer (99)
Cancer (954)
Cardiovascular disease (66)
Career advice (766)
Career pathing (21)
CAR-T (106)
Cell therapy (288)
Cervical cancer (9)
Clinical research (18868)
Collaboration (464)
Company closure (1)
Compensation (131)
Complete response letters (11)
COVID-19 (753)
CRISPR (23)
C-suite (164)
Cystic fibrosis (43)
Data (841)
Denatured (5)
Depression (22)
Diabetes (68)
Diagnostics (1086)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (21)
Drug discovery (69)
Drug pricing (23)
Drug shortages (2)
Duchenne muscular dystrophy (42)
Earnings (16225)
Editorial (19)
Employer branding (8)
Employer resources (69)
Events (31744)
Executive appointments (414)
FDA (2737)
Friedreich's ataxia (2)
Frontotemporal dementia (7)
Funding (396)
Gene editing (61)
Generative AI (12)
Gene therapy (202)
GLP-1 (281)
Government (651)
Grass and pollen (1)
Guidances (41)
Healthcare (2396)
Huntington's disease (19)
IgA nephropathy (16)
Immunology and inflammation (84)
Indications (13)
Infectious disease (816)
Inflammatory bowel disease (75)
Inflation Reduction Act (3)
Influenza (24)
Intellectual property (50)
Interviews (140)
IPO (4122)
IRA (13)
Job creations (1477)
Job search strategy (703)
Kidney cancer (5)
Labor market (30)
Layoffs (188)
Leadership (14)
Legal (1191)
Liver cancer (20)
Lung cancer (106)
Lymphoma (77)
Machine learning (5)
Management (23)
Manufacturing (168)
MASH (26)
Medical device (683)
Medtech (684)
Mergers & acquisitions (5488)
Metabolic disorders (249)
Multiple sclerosis (40)
NASH (8)
Neurodegenerative disease (56)
Neuropsychiatric disorders (13)
Neuroscience (703)
NextGen: Class of 2025 (1446)
Non-profit (455)
Now hiring (20)
Obesity (138)
Opinion (176)
Ovarian cancer (36)
Pain (33)
Pancreatic cancer (35)
Parkinson's disease (56)
Partnered (10)
Patents (89)
Patient recruitment (37)
Peanut (13)
People (22311)
Pharmaceutical (15)
Phase I (7324)
Phase II (9021)
Phase III (5067)
Pipeline (560)
Policy (77)
Postmarket research (306)
Preclinical (3009)
Press Release (61)
Prostate cancer (33)
Psychedelics (18)
Radiopharmaceuticals (84)
Rare diseases (187)
Real estate (2440)
Recruiting (36)
Regulatory (4582)
Reports (21)
Research institute (518)
Resumes & cover letters (152)
Rett syndrome (1)
RNA editing (4)
RSV (13)
Schizophrenia (24)
Series A (89)
Series B (50)
Service/supplier (6)
Sickle cell disease (24)
Special edition (12)
Spinal muscular atrophy (48)
Sponsored (12)
Startups (1787)
State (1)
Stomach cancer (5)
Supply chain (26)
Tariffs (22)
The Weekly (28)
Vaccines (242)
Venture capitalists (38)
Weight loss (94)
Women's health (9)
Worklife (8)
Date
Today (22)
Last 7 days (370)
Last 30 days (1152)
Last 365 days (12043)
2025 (4532)
2024 (12646)
2023 (13201)
2022 (16037)
2021 (16925)
2020 (13178)
2019 (9494)
2018 (7536)
2017 (8976)
2016 (8111)
2015 (9408)
2014 (9724)
2013 (9448)
2012 (6079)
2011 (6451)
2010 (5840)
Location
Africa (326)
Alabama (32)
Alaska (3)
Arizona (50)
Arkansas (2)
Asia (13562)
Australia (2695)
California (2421)
Canada (752)
China (208)
Colorado (42)
Connecticut (95)
Delaware (48)
Europe (30467)
Florida (272)
Georgia (40)
Idaho (13)
Illinois (137)
India (12)
Indiana (119)
Iowa (3)
Japan (68)
Kansas (17)
Kentucky (4)
Louisiana (5)
Maine (2)
Maryland (350)
Massachusetts (1899)
Michigan (80)
Minnesota (129)
Missouri (17)
Montana (8)
Nebraska (4)
Nevada (12)
New Hampshire (7)
New Jersey (623)
New Mexico (11)
New York (603)
North Carolina (395)
North Dakota (5)
Northern California (1035)
Ohio (58)
Oklahoma (7)
Oregon (9)
Pennsylvania (495)
Puerto Rico (3)
Rhode Island (11)
South America (402)
South Carolina (2)
Southern California (952)
Tennessee (19)
Texas (288)
United States (8363)
Utah (30)
Virginia (19)
Washington D.C. (17)
Washington State (353)
Wisconsin (13)
184,875 Results for "dolcas biotech".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Tariffs
Biotech’s ‘Nauseating Roller Coaster’ Repels Investors
Biotech was starting to show signs of recovery after years of investor pullback—until new tariffs and economic uncertainty sent fresh shockwaves through an already fragile market.
April 23, 2025
·
5 min read
·
Ana Mulero
Pharm Country
DolCas Biotech Obtains its First Non-GMO Project Verified Label for MMP-50®
DolCas Biotech, LLC obtains its first Non-GMO Project-verified label for MMP-50®, a cold-processed, DNA-verified, and clinically researched New England green lipped mussel extract for human and pet health.
September 13, 2023
·
4 min read
Government
Lawmakers Seek to Boost US Biotech Sector, Keep China’s Growth in Check
According to analysts at Jefferies, legislation such as the newly proposed bills that aim to streamline regulatory processes would be a positive for the biotech industry.
April 11, 2025
·
2 min read
·
Tristan Manalac
Regulatory
Biotech Leaders Implore Sen. Cassidy To Step Up in Wake of FDA Cuts
Biotech companies are already seeing regulatory delays and plenty of uncertainty after around 3,500 FDA employees were cut by the Trump administration.
April 10, 2025
·
3 min read
·
Annalee Armstrong
China
Amid Trade Tensions, Commission Warns China is ‘Dangerously Close’ to Overtaking US Biotech
The National Security Commission on Emerging Biotechnology recommends at least a $15 billion investment into biotech over the next five years.
April 9, 2025
·
2 min read
·
Tristan Manalac
Executive appointments
Women Leaders Decline in Biotech’s Era of ‘Proven Leadership’
Of the 102 company launches or series A financings since October 2023, just nine had a woman at the helm, according to a
BioSpace
analysis. This is happening in an era of biotech where new company founders are searching for CEOs with a track record.
February 5, 2025
·
8 min read
·
Annalee Armstrong
Business
DolCas Biotech and Clear Within Team Up for Beauty-from-Within Supplement
DolCas Biotech, LLC and its concentrated turmeric extract, Curcugen®, have been selected by nutritional supplement company, Clear Within, for its vegan nutricosmetic.
March 20, 2023
·
4 min read
C-suite
Biotech a Bright Spot for Female Founders Amid DEI Pullback
A new Pitchbook report found $4.3 billion in funding to women-fronted biotech companies across 121 deals. The increase comes as sociopolitical headwinds slam into initiatives to support women and minorities.
March 6, 2025
·
2 min read
·
Annalee Armstrong
Bankruptcy
Bluebird’s Go-Private Deal Highlights Fraught Life Preserver for Struggling Biotechs
Facing declining valuations and funding challenges, public biotechs like bluebird bio are going private to restructure, reduce regulatory burdens and refocus on long-term growth.
March 12, 2025
·
6 min read
·
Ana Mulero
Legal
Novo Seeks $830M in Fraud Case Against Singaporean Biotech Over Kidney Drug
Back in 2023, Novo Nordisk committed up to $1.3 billion for a hypertension and kidney disease drug from KBP Biosciences. Now, the pharma giant claims to have been misled by the biotech’s founder—and a judge seems to agree.
February 18, 2025
·
1 min read
·
Annalee Armstrong
1 of 18,488
Next
